PUBLISHER: DelveInsight | PRODUCT CODE: 1381083
PUBLISHER: DelveInsight | PRODUCT CODE: 1381083
“"NAMUSCLA (Mexiletine) Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about NAMUSCLA for Myotonic Dystrophy in the seven major markets. A detailed picture of the NAMUSCLA for myotonic dystrophy in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the NAMUSCLA for myotonic dystrophy. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the NAMUSCLA market forecast analysis for myotonic dystrophy in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myotonic dystrophy.
NAMUSCLA (Mexiletine) is a generic cardiovascular drug, initially developed to treat heart rhythm abnormalities, and holds some potential for treating muscle stiffness and other symptoms of non-dystrophic myotonias (NDMs). Myotonic dystrophy has as one of its alterations abnormal function of the chloride channel. This causes myotonia and stiffness, and, like the patients with non-dystrophic myotonia, myotonic dystrophy patients show a beneficial response to treatment with NAMUSCLA. Mexiletine slows the rate of movement of sodium ions into muscle cells, reducing or eliminating the tendency of the muscle to maintain a prolonged contraction. This enables the muscle cell to relax properly and prepare for the next contraction. In addition, the US FDA has granted NAMUSCLA ODD to treat myotonic dystrophy. Furthermore, the company is currently conducting two Phase III trials in myotonic dystrophy patients.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
This report provides a detailed market assessment of NAMUSCLA for myotonic dystrophy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.
The report provides the clinical trials information of NAMUSCLA for myotonic dystrophy covering trial interventions, trial conditions, trial status, start and completion dates.